Lilly's weight loss drug makes a major breakthrough! Research shows that terlipressin can significantly reduce the risk of heart failure.
The active ingredient tirzepatide in Lai's flagship weight loss drug Zepbound and diabetes treatment drug Mounjaro can significantly reduce the risk of worsening heart failure in obese adults with heart failure with preserved ejection fraction (HFpEF).
A trial result shows that the effective ingredient tirzepatide in Zepbound, a heavy-weight weight-loss drug, and Mounjaro, a diabetes treatment drug under Lilly (LLY.US), can significantly reduce the risk of heart failure worsening in overweight adults with heart failure preserved ejection fraction (HFpEF). In the phase III study called "SUMMIT", tirzepatide reduced the risk of heart failure worsening in overweight adults with HFpEF by 38% and reduced the risk of hospitalization due to heart failure by 56% compared to placebo. Additionally, patients taking tirzepatide had an average weight loss of 15.7%, while those in the placebo group had an average weight loss of 2.2%.
Currently, there is no specific treatment for obesity-related HFpEF in the United States. The above-mentioned study is the first conducted in obese patients with HFpEF to evaluate the reduction of heart failure events risk and improvement of function as primary endpoints. Data shows that tirzepatide demonstrated statistically significant improvements in both primary endpoints and met all key secondary endpoints. Furthermore, Lilly has submitted an application for tirzepatide for the treatment of obesity-related HFpEF to global regulatory agencies.
Related Articles

Huachu Securities: Shunfeng (06936) continues to lead in the volume growth rate in June, pay attention to investment opportunities in the express delivery sector under the "anti-inner loop" trend.

Guosen: How to make absolute return investments in a low interest rate environment?

Preview of new stocks in the US stock market | Industry anti-involvement helps to repair the fundamentals, how does New Subee Optoelectronics (XZ.US) break into the top tier of the industry?
Huachu Securities: Shunfeng (06936) continues to lead in the volume growth rate in June, pay attention to investment opportunities in the express delivery sector under the "anti-inner loop" trend.

Guosen: How to make absolute return investments in a low interest rate environment?

Preview of new stocks in the US stock market | Industry anti-involvement helps to repair the fundamentals, how does New Subee Optoelectronics (XZ.US) break into the top tier of the industry?

RECOMMEND

For the Third Consecutive Month, China Reduces U.S. Treasury Holdings by $900 Million in May, While Japan and the United Kingdom Increase Holdings
18/07/2025

Tariff-Driven Inflation Arrives with Delay as U.S. Consumers Begin to Feel the Initial Pinch
18/07/2025

Multiple Countries in High-Stakes Talks with the U.S.; EU Considers Invoking “Anti-Coercion Tool” as U.S. Plans Unified Tariffs on 150 Nations
18/07/2025